
## David Tamborero

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5850179/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. Nature Cancer, 2022, 3, 251-261.	5.7	44
2	Discordant Reporting of a Previously Undescribed Pathogenic Germline BRCA2 Variant in Blood and Tumor Tissue in a Patient With Pancreatic Adenocarcinoma. JCO Precision Oncology, 2021, 5, 974-980.	1.5	1
3	Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms. Nature Cancer, 2021, 2, 1224-1242.	5.7	37
4	A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer. Nature Genetics, 2020, 52, 448-457.	9.4	104
5	Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. Nature Medicine, 2020, 26, 992-994.	15.2	56
6	Analyses of non-coding somatic drivers in 2,658Âcancer whole genomes. Nature, 2020, 578, 102-111.	13.7	424
7	CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase. Leukemia, 2019, 33, 518-558.	3.3	15
8	A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations. Clinical Cancer Research, 2018, 24, 3717-3728.	3.2	267
9	Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell, 2018, 173, 371-385.e18.	13.5	1,670
10	Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations. Genome Medicine, 2018, 10, 25.	3.6	366
11	CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer. Nature Genetics, 2017, 49, 170-174.	9.4	460
12	JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell–induced protection of AML. Blood, 2017, 130, 789-802.	0.6	90
13	Comparison of algorithms for the detection of cancer drivers at subgene resolution. Nature Methods, 2017, 14, 782-788.	9.0	72
14	Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing. Oncotarget, 2017, 8, 56338-56350.	0.8	35
15	A Landscape of Pharmacogenomic Interactions in Cancer. Cell, 2016, 166, 740-754.	13.5	1,518
16	Rational design of cancer gene panels with OncoPaD. Genome Medicine, 2016, 8, 98.	3.6	5
17	In Silico Prescription of Anticancer Drugs to Cohorts of 28 Tumor Types Reveals Targeting Opportunities. Cancer Cell, 2015, 27, 382-396.	7.7	290
18	Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature, 2015, 526, 519-524.	13.7	749

DAVID TAMBORERO

#	Article	IF	CITATIONS
19	Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nature Genetics, 2015, 47, 106-114.	9.4	830
20	OncodriveROLE classifies cancer driver genes in loss of function and activating mode of action. Bioinformatics, 2014, 30, i549-i555.	1.8	49
21	Fast randomization of large genomic datasets while preserving alteration counts. Bioinformatics, 2014, 30, i617-i623.	1.8	36
22	Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia. Genome Research, 2014, 24, 212-226.	2.4	175
23	Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin. Cell, 2014, 158, 929-944.	13.5	1,242
24	Integration of Ex Vivo Drug Testing and in-Depth Molecular Profiling Reveals Oncogenic Signaling Pathways and Novel Therapeutic Strategies for Multiple Myeloma. Blood, 2014, 124, 2046-2046.	0.6	3
25	Landscape of Driver Lesions in Multiple Myeloma and Consequences for Targeted Drug Response. Blood, 2014, 124, 3351-3351.	0.6	0
26	OncodriveCLUST: exploiting the positional clustering of somatic mutations to identify cancer genes. Bioinformatics, 2013, 29, 2238-2244.	1.8	397
27	Comprehensive identification of mutational cancer driver genes across 12 tumor types. Scientific Reports, 2013, 3, 2650.	1.6	437
28	IntOGen-mutations identifies cancer drivers across tumor types. Nature Methods, 2013, 10, 1081-1082.	9.0	517
29	Oncodrive-CIS: A Method to Reveal Likely Driver Genes Based on the Impact of Their Copy Number Changes on Expression. PLoS ONE, 2013, 8, e55489.	1.1	29
30	Comparison of Hemodynamic versus Dyssynchrony Assessment for Interventricular Delay Optimization with Echocardiography in Cardiac Resynchronization Therapy. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 984-990.	0.5	9
31	Electrocardiographic versus Echocardiographic Optimization of the Interventricular Pacing Delay in Patients Undergoing Cardiac Resynchronization Therapy. Journal of Cardiovascular Electrophysiology, 2011, 22, 1129-1134.	0.8	48
32	Effect of Repeated Radiofrequency Catheter Ablation on Left Atrial Function for the Treatment of Atrial Fibrillation. American Journal of Cardiology, 2011, 108, 1741-1746.	0.7	27
33	Low efficacy of atrial fibrillation ablation in severe obstructive sleep apnoea patients. Europace, 2010, 12, 1084-1089.	0.7	138
34	Left ventricular systolic dysfunction by itself does not influence outcome of atrial fibrillation ablation. Europace, 2010, 12, 24-29.	0.7	73
35	Efficacy of circumferential pulmonary vein ablation of atrial fibrillation in endurance athletes. Europace, 2010, 12, 30-36.	0.7	109
36	Survival in New York Heart Association class IV heart failure patients treated with cardiac resynchronization therapy compared with patients on optimal pharmacological treatment. Europace, 2010, 12, 1136-1140.	0.7	31

DAVID TAMBORERO

#	Article	IF	CITATIONS
37	Plasma tissue inhibitor of matrix metalloproteinaseâ€1 (TIMPâ€1): an independent predictor of poor response to cardiac resynchronization therapy. European Journal of Heart Failure, 2010, 12, 492-498.	2.9	16
38	Circumferential pulmonary vein ablation: Does use of a circular mapping catheter improve results? A prospective randomized study. Heart Rhythm, 2010, 7, 612-618.	0.3	29
39	Six-minute walking test predicts long-term cardiac death in patients who received cardiac resynchronization therapy. Europace, 2009, 11, 338-342.	0.7	30
40	Left Atrial Posterior Wall Isolation Does Not Improve the Outcome of Circumferential Pulmonary Vein Ablation for Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2009, 2, 35-40.	2.1	129
41	Preparation for pacemaker or implantable cardiac defibrillator implants in patients with high risk of thrombo-embolic events: oral anticoagulation or bridging with intravenous heparin? A prospective randomized trial. European Heart Journal, 2009, 30, 1880-1884.	1.0	104
42	Midterm 'super-response' to cardiac resynchronization therapy by biventricular pacing with fusion: insights from electro-anatomical mapping. Europace, 2009, 11, 1675-1682.	0.7	47
43	Noninvasive Evaluation of Radiofrequency Lesions in the Human Ventricular Myocardium by Contrast-Enhanced Cardiac Magnetic Resonance. Circulation: Arrhythmia and Electrophysiology, 2009, 2, 208-211.	2.1	7
44	Electrocardiographic Optimization of Cardiac Resynchronization Devices: Simple, but Not So Simple!. American Journal of Cardiology, 2009, 103, 894.	0.7	2
45	Optimization of the Interventricular Delay in Cardiac Resynchronization Therapy Using the QRS Width. American Journal of Cardiology, 2009, 104, 1407-1412.	0.7	39
46	Cardiac Motion Estimation from Intracardiac Electrical Mapping Data: Identifying a Septal Flash in Heart Failure. Lecture Notes in Computer Science, 2009, , 21-29.	1.0	7
47	Left Atrial Contractility is Preserved After Successful Circumferential Pulmonary Vein Ablation in Patients with Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2008, 19, 374-379.	0.8	47
48	Fate of Left Atrial Function as Determined by Real-Time Three-Dimensional Echocardiography Study After Radiofrequency Catheter Ablation for the Treatment of Atrial Fibrillation. American Journal of Cardiology, 2008, 101, 1285-1290.	0.7	58
49	Comparison of Benefits and Mortality in Cardiac Resynchronization Therapy in Patients With Atrial Fibrillation Versus Patients in Sinus Rhythm (Results of the Spanish Atrial Fibrillation and) Tj ETQq1 1 0.784314 r	gB <b>ō.</b> #Over	lock010 Tf 50
50	Gender Differences in Clinical Manifestations of Brugada Syndrome. Journal of the American College of Cardiology, 2008, 52, 1567-1573.	1.2	265
51	Physical activity, height, and left atrial size are independent risk factors for lone atrial fibrillation in middle-aged healthy individuals. Europace, 2008, 10, 15-20.	0.7	237
52	Cooled-tip vs. 8 mm-tip catheter for circumferential pulmonary vein ablation: comparison of efficacy, safety, and lesion extension. Europace, 2008, 10, 955-960.	0.7	18
53	Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation. European Heart Journal, 2007, 28, 836-841.	1.0	351
54	Is there an anatomical substrate for idiopathic paroxysmal atrial fibrillation? A case–control echocardiographic study. Europace, 2007, 9, 294-298.	0.7	27

DAVID TAMBORERO

#	Article	IF	CITATIONS
55	Predictors of arrhythmia recurrence in patients with lone atrial fibrillation. Europace, 2007, 10, 9-14.	0.7	23
56	Electrocardiographic Optimization of Interventricular Delay in Cardiac Resynchronization Therapy: A Simple Method to Optimize the Device. Journal of Cardiovascular Electrophysiology, 2007, 18, 1252-1257.	0.8	57
57	Usefulness of Ventricular Dyssynchrony Measured Using M-Mode Echocardiography to Predict Response to Resynchronization Therapy. American Journal of Cardiology, 2007, 100, 84-89.	0.7	29
58	Optimizing the Programation of Cardiac Resynchronization Therapy Devices in Patients With Heart Failure and Left Bundle Branch Block. American Journal of Cardiology, 2007, 100, 1002-1006.	0.7	84
59	Selective segmental ostial ablation and circumferential pulmonary veins ablation. Results of an individualized strategy to cure refractory atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2007, 19, 19-27.	0.6	6
60	Anodal Capture in Cardiac Resynchronization Therapy Implications for Device Programming. PACE - Pacing and Clinical Electrophysiology, 2006, 29, 940-945.	0.5	34
61	Relation of Response to Cardiac Resynchronization Therapy to Left Ventricular Reverse Remodeling. American Journal of Cardiology, 2006, 97, 876-881.	0.7	32
62	Incidence of Pulmonary Vein Stenosis in Patients Submitted to Atrial Fibrillation Ablation: A Comparison of the Selective Segmental Ostial Ablation vs the Circumferential Pulmonary Veins Ablation. Journal of Interventional Cardiac Electrophysiology, 2005, 14, 21-25.	0.6	40
63	Electrocardiographic optimization of interventricular delay in cardiac resynchronization therapy: Correlation with echocardiography. Heart Rhythm, 2005, 2, S289.	0.3	1